Navigation Links
Cambridge Laboratories Announces Approval of Tetrabenazine in Spain
Date:12/8/2008

DUBLIN and NEWCASTLE, England, December 8 /PRNewswire/ --

- Marketing Partner UCB Expects to Receive Completed Price and Reimbursement Approval for Tetrabenazine in H1 2009

- Exclusive Distribution Rights Granted in Finland (MediFront) and Taiwan (Giddi Pharma); Distribution Contracts Renewed in Australia and New Zealand

Cambridge Laboratories Limited ("Cambridge" or "the Company"), the privately-owned specialty pharmaceutical company, today announces that its flagship product Tetrabenazine, (known as NITOMAN(R) in Germany and other key European territories and XENAZINE(R) in the UK, US and other markets) has received marketing approval in Spain from the Agencia Espanola de Medicamentos y Productos Sanitarios.

The Company also announces that it has recently signed distribution agreements for Tetrabenazine in Finland and Taiwan, and renewed existing arrangements in Australia and New Zealand.

Tetrabenazine will be marketed as NITOMAN(R) in Spain by Cambridge's marketing partner UCB upon successful completion of all related procedures. It has been approved for the treatment of movement disorders associated with Huntington's disease, a condition for which there is major unmet medical need.

Cambridge has recently renegotiated its agreements with UCB in Spain and Portugal, giving UCB ten year exclusive marketing rights to Tetrabenazine in Spain. UCB, a global biopharmaceutical company, is focused on severe diseases in three therapeutic areas - inflammation, oncology and neurology. The renegotiated terms follow UCB's acquisition of Celltech, Cambridge's former partner in Spain and Portugal, and the more recent merger of UCB with Schwarz Pharma.

UCB is currently in the process of applying for price and reimbursement in Spain and expects to have this procedure completed in the first half of 2009.

Mark Evans, CEO of Cambridge, said: "The granting of a
'/>"/>

SOURCE Cambridge Laboratories Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
2. IBT Laboratories Expands its Menu of Tests for Immune Deficiency
3. Roxane Laboratories, Inc. Updated Launch of Calcium Acetate Capsules, 667mg
4. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
5. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
6. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
7. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
8. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
9. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
10. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
11. Romark Laboratories Raises $18 Million in Institutional Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... KIRKLAND, Wash. , Aug. 19, 2014 ... solutions, will be exhibiting at the 2014 NPPA Summer ... The company will be showcasing its 340B software products ... leader in 340B splitting solutions, supplying over 400 customers ... a range of 340B solutions including its latest solution, ...
(Date:8/19/2014)... YORK , Aug. 19, 2014 /PRNewswire-iReach/ -- ChemImage ... will present a scientific poster describing an innovative diagnostic ... SPEC 2014: Shedding New Light on Disease (SPEC) conference ... Dr. Treado,s poster entitled, "Development of in vitro ... Imaging" will be discussed during the conference poster session ...
(Date:8/19/2014)... , Aug. 19, 2014  Tokyo-based Atonarp Inc. ... funding round led by Walden Riverwood Ventures with ... development of Atonarp,s Smart Spectrometer technology platform, which ... company has targeted the oil & gas and ... "We are excited to partner with Atonarp in ...
Breaking Medicine Technology:Talyst Exhibits at the NPPA Summer Conference 2ChemImage Scientists Present Latest Developments for in vitro Detection of Colorectal Cancer Using Raman Molecular Imaging (RMI) at International Conference Focused on Biomedical Applications of Raman Spectroscopy 2Atonarp Inc. Raises $8M Series A Round Led by Walden Riverwood Ventures 2
... China Botanic Pharmaceutical Inc. (AMEX: CBP ) ... distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ... the Company,s new Chief Financial Officer ("CFO") on December ... over 10 years with key positions in finance, audit, ...
... Calif. and LUXEMBOURG, Dec. 16, 2010 WaferGen Biosystems, ... leading developer of state-of-the-art genomic analysis systems, and the ... to establish a strategic relationship that will expand the ... Europe and advance personalized medicine.   The ...
Cached Medicine Technology:China Botanic Appoints David Dong as New Chief Financial Officer 2China Botanic Appoints David Dong as New Chief Financial Officer 3WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 2WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 3WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 4WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 5
(Date:8/20/2014)... GA (PRWEB) August 20, 2014 ... to healthcare, Jvion successfully predicted stage iii and ... that, in some situations, approached 90%. A company ... been achieved in commercial or academic settings. The ... prevent all types of hospital-acquired conditions to help ...
(Date:8/20/2014)... Oshkosh, Wisconsin (PRWEB) August 20, 2014 ... to the general public at fair prices. The well-known ... ability, and she is now touring in 19 cities, ... locations where the television personality will visit are Albany, ... Kalamazoo, Colorado Springs, Albuquerque, Beverly Hills and San Diego. ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Blaine ... the innovative RevitaDERM® Psoriasis Treatment to ... associated with psoriasis. This all-in-one product was created ... RevitaDERM® Psoriasis Treatment is powered by coal tar ... associated with this effective ingredient. , RevitaDERM® ...
(Date:8/20/2014)... August 20, 2014 The “Human ... Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid ... Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast to ... drivers,restraints, challenges, opportunities, current market trends,and strategies impacting ... estimates and forecasts of the revenue and share ...
(Date:8/20/2014)... 20, 2014 AttorneyOne.com, a recognized authority on ... from the FDA on Sodium Chloride IV . ... lot of Sodium Chloride IV 0.9%, USP 1000 mL, by ... presence of particulate matter. Sodium Chloride Injection, USP is used ... priming solution in hemodialysis procedures. , The reason ...
Breaking Medicine News(10 mins):Health News:Jvion Achieves Benchmark Accuracy in Pressure Ulcer Prediction 2Health News:Theresa Caputo Tour Tickets for Sale at Ticketability.com Cause a Buying Frenzy Among Customers Over Their Offering of Deeply Discounted Seats 2Health News:RevitaDERM® Psoriasis Treatment Now Available At Over 7,600 CVS/pharmacies 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Sodium Chloride IV 0.9% by Baxter Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2
... Steven Reinberg HealthDay Reporter , WEDNESDAY, Aug. 3 ... detect prostate cancer and better evaluate a patient,s treatment options, ... their physician can use to help them decide whether it,s ... said lead researcher Dr. Scott Tomlins, a pathology resident at ...
... , WEDNESDAY, Aug. 3 (HealthDay News) -- Many Americans believe ... is, a new survey finds. The telephone poll of ... be like a video camera that records detailed information for ... the participants believed that once experiences are stored as memory, ...
... , Arriving at a rapid and accurate diagnosis is critical ... officials have had to choose between a highly accurate yet ... new detection method developed at the University of Georgia and ... however, offers the best of both worlds. By coating ...
... Mayo Clinic orthopedic surgeon suspects that the nagging pain ... may be different from what men encounter, and she ... to explore the question. The Society for Women,s Health ... Network on Musculoskeletal Health has awarded a group of ...
... News) -- Vampire bats have heat-detecting molecules that help guide ... long been known that vampire bats know where to bite ... a vein, but the researchers believe this is the first ... Venezuelan researchers investigated wild vampire bats in South America and ...
... ranging from artificial hip joints to dentures and catheters, become ... called biofilms that are resistant to the human immune system ... However, researchers may have a new way of looking ... Iowa biologist David Soll and his colleagues published in the ...
Cached Medicine News:Health News:Urine Test Might Help Predict Prostate Cancer Risk 2Health News:Urine Test Might Help Predict Prostate Cancer Risk 3Health News:Memories Can Be Unreliable, Manipulated 2Health News:UGA researchers use gold nanoparticles to diagnose flu in minutes 2Health News:UGA researchers use gold nanoparticles to diagnose flu in minutes 3Health News:Mayo Clinic examines why knee osteoarthritis afflicts more women than men 2
Inquire...
Inquire...
... Optimal for Subcellular Fractionation, ... x g (30,000 rpm) with ... from 0.25 up to 85 ... 2° C to 40° C ...
... Fractionation, Proteins and Viruses • ... with fixed-angle rotor • Spin ... 85 mL • Operating temperature ... C • Rotors certified by ...
Medicine Products: